Presseinformationen weltweit an Journalisten und Leser verbreiten
CorFlow Therapeutics AG ("CorFlow") today announced that the first two patients have been enrolled into the First-in-Man (FIM) MOCA I clinical trial. The first MOCA (Microvascular Obstruction with the CoFITM System Assessment) trial is a safety and feasibility trial assessing the CorFlow Controlled Mehr
CorFlow Therapeutics AG ("CorFlow") announced that the US Patent Office (USPTO) this week granted the company it’s first US patent, US Patent No. 10,315,016 "System and methods for treating MVO", which protects CorFlow’s Controlled Flow Infusion (CoFI™) method for diagnosing and provide a Mehr
CorFlow Therapeutics AG ("CorFlow") today announced that the company will present the Controlled Flow Infusion (CoFI™) technology for diagnosis and treatment of microvascular obstruction in patients with myocardial infarction during the upcoming PCR Innovators Day, to be held in Paris, France. Mehr
CorFlow Therapeutics AG ("CorFlow") today announced that the Swiss competent authority, Swissmedic, and the Swiss ethics committee, Swissethics, have approved the company’s MOCA I study, which is a three phased First-in-Man clinical trial. The first MOCA (Microvascular Obstruction with the CoFITM Mehr
CorFlow Therapeutics AG ("CorFlow") today announced that it is restructuring it’s management team. It is with great pleasure that CorFlow announces the arrival of Mr. Timothy Snyder as Chief Financial Officer (CFO). Tim joined the company in December 2018 and brings with Mehr
CorFlow Therapeutics AG ("CorFlow") today announced that Innosuisse, the Swiss Innovation Agency, has awarded the Company a non-dilutive public grant. The grant is a continuation of the successfully completed non-clinical project which was granted by CTI/Innosuisse in January 2017. Innosuisse’s role is Mehr